ArticleJournal of immunology research2026
Induced Regulatory T Cells Attenuate Poly I:C-Triggered Acute Lung Injury by Modulating Cytokine Responses.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Induced Regulatory T Cells Attenuate Poly I:C-Triggered Acute Lung Injury by Modulating Cytokine Responses.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
objectiveAcute lung injury (ALI) is characterized by severe pulmonary inflammation and edema and carries a high risk of mortality. This study aimed to evaluate the therapeutic potential of induced regulatory T cells (iTregs) as an early intervention to mitigate ALI using a polyinosinic-polycytidylic acid (poly I:C)-induced murine model.
methodsC57BL/6 mice were intratracheally administered the synthetic double-stranded RNA (dsRNA) analog poly I:C to induce a hyperinflammatory response, followed by intravenous injection of iTreg 1 h later to target the early phase of injury progression.
resultsAnalysis of bronchoalveolar lavage fluid (BALF) from poly I:C-treated mice revealed significantly elevated proinflammatory cytokines (interleukin [IL])-6, IL-12, TNF-α, interferon [IFN]-β, and IP-10), decreased anti-inflammatory cytokines (IL-10 and transforming growth factor [TGF-β]), increased infiltration of neutrophils, monocytes, and lymphocytes, and evident alveolar damage with thickened walls and edema. Early iTreg administration effectively reversed these effects by suppressing proinflammatory cytokines, restoring IL-10 levels, reducing immune cell infiltration, and mitigating tissue damage.
conclusionsThese findings demonstrate that iTreg therapy effectively modulates the hyperinflammatory response in ALI and may represent a promising strategy for treating severe inflammatory lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.